Clinical Trial Search

Primary: Number of Brain Scans in Healthy Young Adults Subjects Which do Not Show Amyloid — 181; 0; 123; 58 Brain Scans Read

Primary: Change in Amyloid Burden — -1.55 dSUVR

Primary: Relationship Between Cognitive Change Over Time and Amyloid (Aβ) Deposition — 41; 75 Participants — p=0.02

Primary: Difference in Amyloid-beta (Abeta) Concentration in the CSF (Cerebral Spinal Fluid) of Individuals With Poor Sleep Efficiency Compared to Those With Good Sleep…

Primary: Percent Increase From Mean Baseline (07:00 to 19:00) of Cerebrospinal Fluid (CSF) Amyloid Beta During Sleep Induction and Sleep Deprivation Between 01:00 and 11:00 From…

Primary: Influence of the Neuroimaging Test on a Finding of Alzheimer's Disease as the Underlying Cause of the Mild Memory Loss — 3; 12; 9; 31 participants

Primary: Change From Baseline to Day 2 in Cerebrovascular Reactivity as Measured by the Slope (Amplitude Over Time to Peak) From Visual Task-evoked Functional Magnetic Resonance…

Primary: 11C-PBR28 Binding — 1.25; 1.15; 1.16; 1.02 SUVR

Primary: Amyloid Beta Levels in CSF — -12.7; 6.74; -22.73; -25.63 pg/mL

Primary: Mean Cortical Amyloid Burden — 0.990; 1.051; 1.146 SUVR

Primary: Sensitivity of the Independent Visual Assessment of Detecting Cerebral Amyloid-beta in Individuals With Down Syndrome and Specificity in Subjects Without Down Syndrome…

Primary: Change From Baseline in Aβ1-42 Cerebrospinal Fluid (CSF) Levels. — 75.3; -45.5; -86.2; -283.0 pg/mL

Primary: Amyloid Deposition Obtained on a 18F-flutemetamol Brain Scan. — 1.65 ratio of flutemetamol absorbed — p=<0.05

Primary: Number of Subjects Retained at 6 Months — 11; 4 Participants

Primary: Average Maximal Increment of Anti-Aβ40 Antibody Signal (Optical Density [OD] in ELISA) — 0.12; 3.27 OD — p=<0.0001

Primary: Changes in Cerebrospinal Fluid (CSF) Beta-amyloid-42 Levels Compared to Baseline as Measured by xMAP — 1.01; 0.98 ratio

Primary: Change From Baseline in Brain Fibrillar Beta-Amyloid Protein (Aβ) at Week 104 as Measured by Standard Uptake Value Ratios (SUVRs) Over the Composite Regions of Interest…

Primary: Drug-Placebo Difference in Change From Baseline to Week 4 in the Composite Amyloid Burden of the Brain — -0.03; 0.02 SUVr — p=0.22

Primary: Word List Memory Total - ADAS-cog — 14.35; 14.7; 15.1; 14.67 Words recalled

Primary: Side Effects — 0.53 units on a scale

Primary: Change From Baseline in Alzheimer's Disease Assessment Scale- Cognitive Subscale (ADAS-Cog11) at 76 Weeks — 7.37; 6.77 units on a scale — p=0.560

Primary: Correlation of Florbetapir-PET Image and Amyloid Plaque Density — 0.78 Correlation coefficient — p=<0.0001

Primary: Amyloid Burden — 1.20; 1.22; 1.21; 1.22 Standard Uptake Value Ratio (SUVR)

Primary: Changes in Gray Matter Intracranial Pulsatility — -0.09; 0.02 mm/cardiac cycle

Primary: Regional Cerebral Blood Flow Using Arterial Spin-labeling MRI — 55.7; 54.5 mL/g/min — p=0.17

Primary: Percentage of Adherence to Daily Device Use — 95.55; 95.37 percentage of adherence to treatment

Primary: Difference in Cerebrospinal Fluid (CSF) Soluble Alpha-clevaed Amyloid Precursor Protein (APPsα) Concentration at Visit 3 Compared to Baseline — 1.251; 0.8741 fold change…

Primary: Participant Interest in PET Biomarker Disclosure — 73 Participants

Primary: Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog11) Score at 76 Weeks — 6.19; 7.29; 7.68 units on a scale — p=0.134

Primary: The Sensitivity of Blinded Visual Interpretations of [18F]Flutemetamol Positron Emission Tomography (PET) Images Without Anatomic Brain Images for Detecting Brain…